Monoclonal Antibodies In Veterinary Health Market Dynamics 2026: Future Outlook and Key Insights
Uncover key drivers, emerging technologies, and competitive movements shaping the cell therapy manufacturing automation market from 2026–2035 with trusted insights from The Business Research Company
What growth pattern is forecast for the Monoclonal Antibodies In Veterinary Health Market size between 2026 and 2035?
The monoclonal antibodies in veterinary health market has shown significant expansion over recent years. It is forecast to increase from $0.92 billion in 2025 to $1.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.2%. Historically, this market’s expansion was propelled by factors such as the growing occurrence of canine cancers, an uptick in autoimmune disorders among pets, a limited supply of specific targeted therapies, the proliferation of veterinary hospitals, and heightened recognition of sophisticated veterinary treatments.
The monoclonal antibodies in veterinary health market is projected to experience substantial growth over the coming years, reaching $1.85 billion by 2030, driven by a compound annual growth rate (CAGR) of 14.8%. This expansion during the forecast period is fueled by several factors, including technological innovations in mAb engineering, the growing uptake of species-specific treatments, increased investments in veterinary oncology and dermatology, the rise of personalized veterinary medicine, and the broader development of global veterinary healthcare infrastructure. Key trends expected during this period involve the proliferation of monoclonal antibody-based treatments for canine cancer, the increasing application of mabs for autoimmune conditions in dogs, the broadening scope of veterinary dermatology uses, a greater embrace of targeted pain management solutions, and the creation of species-specific antibody therapies for cats, horses, and livestock.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20575&type=smp
Which Drivers Are Impacting Market Performance In The Monoclonal Antibodies In Veterinary Health Market?
An escalation in animal disease occurrences is projected to stimulate the expansion of the monoclonal antibodies in veterinary health market going forward. This heightened frequency of animal diseases is fueled by intensive farming practices, which elevate the potential for infectious disease transmission, as well as by climate change, which broadens the territories of disease vectors such as ticks and mosquitoes. Monoclonal antibodies are notably effective for addressing animal ailments since they pinpoint particular pathogens or proteins engaged in disease processes, thus delivering accurate and potent therapies. For example, in June 2024, a report released by GOV.UK, a UK-based government website, indicated that from April 2023 to March 2024, the quantity of animals culled due to TB incidents saw a 5% increase in England, reaching 21,298, and a 17% increase in Wales, reaching 11,197. Consequently, the rising animal disease incidences are propelling the growth of the monoclonal antibodies in veterinary health market.
Which Segments Are Contributing To The Growth Of The Monoclonal Antibodies In Veterinary Health Market?
The monoclonal antibodies in veterinary health market covered in this report is segmented –
1) By Product: Monoclonal Antibodies (mAbs), Glucocorticoids, Antihistamines, Immunosuppressants, Other Products
2) By Animal Type: Dogs, Cats, Horses, Livestock, Other Animals
3) By Indication: Allergic Skin Disease, Autoimmune Disorders, Infectious Diseases, Cancer Or Tumor Therapy, Other Indications
4) By Route Of Administration: Injectable, Oral, Topical
5) By Distribution Channel: Veterinary Clinics, Specialized Animal Hospitals, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies: Lokivetmab, Felvetmab, Investigational Monoclonal Antibodies, Equine-specific mAbs
2) By Glucocorticoids: Prednisone, Prednisolone, Dexamethasone, Methylprednisolone, Hydrocortisone, Triamcinolone
3) By Antihistamines: Diphenhydramine, Hydroxyzine, Cetirizine, Loratadine, Chlorpheniramine
4) By Immunosuppressants: Cyclosporine, Tacrolimus, Azathioprine, Mycophenolate Mofetil
5) By Other Products: Essential Fatty Acid Supplements, Medicated Shampoos And Sprays, Allergen-Specific Immunotherapy (ASIT), Skin Barrier Repair Creams, Nutraceuticals And Probiotics
What Trends Are Projected To Support The Growth Of The Monoclonal Antibodies In Veterinary Health Market?
Leading companies within the monoclonal antibodies in veterinary health market are dedicated to creating advanced veterinary therapeutic solutions, such as anti-NGF monoclonal antibody treatments designed to alleviate chronic pain and inflammation in animals. This anti-NGF monoclonal antibody treatment functions by targeting and inhibiting nerve growth factor (NGF) to lessen discomfort and inflammation in animals experiencing persistent pain conditions. For example, in May 2023, Zoetis, a US-based animal health company, obtained FDA clearances for Librela (bedinvetmab injection), the initial monoclonal antibody treatment for controlling pain linked with osteoarthritis (OA) in dogs, administered via a once-monthly injection, and Apoquel Chewable, the inaugural chewable medication specifically formulated for managing allergic itch and inflammation in dogs aged one year or older. Librela is a monoclonal antibody that specifically targets and inhibits nerve growth factor (NGF). By obstructing NGF, Librela effectively prevents these pain signals from reaching the brain, thereby diminishing the sensation of pain in dogs afflicted with osteoarthritis. Librela signifies a considerable leap forward in veterinary pain management, offering an innovative method for treating chronic pain in dogs.
Who Are The Top-Performing Companies In The Monoclonal Antibodies In Veterinary Health Market In Recent Years?
Major companies operating in the monoclonal antibodies in veterinary health market are Zoetis Inc, Boehringer Ingelheim International GmbH, MSD Animal Health, Elanco Animal Health Incorporated, Heska Corporation, Ceva Santé Animale S.A., Biogénesis Bagó S.A., PetMedix Ltd, Merck & Co Inc, Virbac SA, Kindred Biosciences Inc, Dechra Pharmaceuticals, Vetigenics, Akston Biosciences Corporation, MabGenesis Inc, IDEXX Laboratories Inc, Nexvet Biopharma, Epitopix LLC, Indian Immunologicals Ltd, Vetoquinol, Phibro Animal Health, Norbrook Laboratories, AnimalCare, Eco Animal Health, Venkys, Hester Biosciences Limited, ImmuCell
Access The Complete Report For Deeper Market Insights:
Which Region Currently Holds The Largest Share Of The Monoclonal Antibodies In Veterinary Health Market?
North America was the largest region in the monoclonal antibodies in veterinary health market in 2025. The regions covered in the monoclonal antibodies in veterinary health market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Monoclonal Antibodies In Veterinary Health Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20575&type=smp
Browse Through More Reports Similar to the Global Monoclonal Antibodies In Veterinary Health Market 2026, By The Business Research Company
Veterinary Reference Laboratory Global Market Report 2026
Veterinary Stereotactic Radiosurgery System Global Market Report 2026
Veterinary Active Pharmaceutical Ingredients Manufacturing Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
